Randomized, parallel assignment, open-label, prospective Phase 2 trial (NCT03920397) comparing adipose-derived stromal/stem cells plus cholecalciferol to cholecalciferol alone in patients with recent-onset T1D. Adverse effects will be recorded. In addition, glycated hemoglobin, insulin dose, frequency of hypoglycemia, glycemic variability, % of time in hyper and hypoglycemia and peak response of the C-peptide after the MMTT will be measured at three-month intervals for a 24-month period (65). Here, INS is linked to Hypoglycemia.